Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602699 · ClinicalTrials.gov registry record · Phase 2
Multi-Site Trial of Tirzepatide for Smoking Cessation
A Phase 2 study, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07602699 is a Phase 2 study that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 300 participants.
The verdict
NCT07602699, a Phase 2 study, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg/m2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg/week; final dose: 10mg/week). All participants will also receive nicotine patches.
Interventions
- DRUG Tirzepatide
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-05-31 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07602699
The ClinicalTrials.gov registry entry for NCT07602699 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07602699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07602699 about?
NCT07602699 is a clinical study titled "Multi-Site Trial of Tirzepatide for Smoking Cessation". This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass ...
What is the current status of trial NCT07602699?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-05-31. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07602699?
The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT07602699?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.